Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review of Autologous Stem Cell Transplantation in Lymphoma
Umar Zahid, Faisal Akbar, Akshay Amaraneni, et al.
Current Hematologic Malignancy Reports (2017) Vol. 12, Iss. 3, pp. 217-226
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L. Locke, David B. Miklos, Caron A. Jacobson, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 7, pp. 640-654
Open Access | Times Cited: 1024
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Mahmoud Elsawy, Julio C. Chávez, Irit Avivi, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2248-2260
Open Access | Times Cited: 44
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Mireia Uribe‐Herranz, Nela Klein-González, Luis Gerardo Rodríguez‐Lobato, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1026-1026
Open Access | Times Cited: 54
Assessment of Predictive Scoring System for 90-Day Mortality Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Completed Concurrent Chemoradiotherapy
Kuan‐Chou Lin, Tsung-Ming Chen, Kevin Sheng‐Po Yuan, et al.
JAMA Network Open (2020) Vol. 3, Iss. 3, pp. e1920671-e1920671
Open Access | Times Cited: 40
Nanomedicine as a magic bullet for combating lymphoma
Srushti Mahajan, Mayur Aalhate, Santosh Kumar Guru, et al.
Journal of Controlled Release (2022) Vol. 347, pp. 211-236
Closed Access | Times Cited: 20
Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)
B. Fulbert, T. K. Chow Vincent, Justine Clarenne, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy
Hyoung‐Il Kim, Haerim Chung, Hye Won Kook, et al.
Blood Research (2025) Vol. 60, Iss. 1
Open Access
What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine—The Current State of Knowledge
Daria Będkowska, Sara Al-Ameri, Aneta Wieczorek, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 596-596
Open Access
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma
Shalev Fried, Roni Shouval, Moneeza Walji, et al.
Transplantation and Cellular Therapy (2022) Vol. 29, Iss. 2, pp. 99-107
Closed Access | Times Cited: 16
Sex-based Differences in Risk for Therapy-related Myeloid Neoplasms
Melissa A. Richard, Chengcheng Yan, Yan-Jun Chen, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3739-3750
Closed Access | Times Cited: 3
Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells
Deepak Bhere, Sung Hugh Choi, Pim van de Donk, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Leukapheresis for CAR-T cell production and therapy
Ilias Pessach, Arnon Nagler
Transfusion and Apheresis Science (2023) Vol. 62, Iss. 6, pp. 103828-103828
Closed Access | Times Cited: 8
Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma
Caixia Li, Ying Zhang, Changfeng Zhang, et al.
JCI Insight (2019) Vol. 4, Iss. 17
Open Access | Times Cited: 24
miR‐203a—A multifaceted regulator modulating cancer hallmarks and therapy response
Priyajit Biswal, Anthony Lalruatfela, Subham Kumar Behera, et al.
IUBMB Life (2023) Vol. 76, Iss. 3, pp. 108-124
Closed Access | Times Cited: 7
Label-free on chip quality assessment of cellular blood products using real-time deformability cytometry
Konstanze Aurich, Bob Fregin, Raghavendra Palankar, et al.
Lab on a Chip (2020) Vol. 20, Iss. 13, pp. 2306-2316
Closed Access | Times Cited: 20
Challenges for cancer patients returning home during SARS-COV-19 pandemic after medical tourism - a consensus report by the emirates oncology task force
Humaid O. Al‐Shamsi, Ibrahim Abu-Gheida, Shabeeha Rana, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 18
Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
Lorenzo Iovino, Qian Wu, Jenna Voutsinas, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 24, pp. 5976-5983
Open Access | Times Cited: 10
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
Katharina Kriegsmann, Max Bittrich, Sandra Sauer, et al.
Transfusion Medicine and Hemotherapy (2023) Vol. 50, Iss. 5, pp. 403-416
Open Access | Times Cited: 6
Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism
Francesca Miglietta, Luca Iamartino, Gaia Palmini, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 5
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Ran Wu, Liyuan Ma
Cell Transplantation (2023) Vol. 32
Open Access | Times Cited: 5
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Sattva S. Neelapu, Sherry Adkins, Stephen M. Ansell, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001235-e001235
Open Access | Times Cited: 14
Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review)
Hye‐Rim Lee, Kwang‐Hyun Baek
Oncology Reports (2019)
Open Access | Times Cited: 12
A review of pathobiology and therapies for classic Hodgkin lymphoma
Maliha Khan, Fredrick Hagemeister, Michael Wang, et al.
Blood Reviews (2022) Vol. 55, pp. 100949-100949
Closed Access | Times Cited: 8
Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis
Sulaiman Mohammed Alnasser, Khalid Saad Alharbi, Ali F. Almutairy, et al.
Cells (2023) Vol. 12, Iss. 24, pp. 2855-2855
Open Access | Times Cited: 4
Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas
Sha Zhou, Jun Rao, Xiang-Yu Ma, et al.
International Journal of Hematology (2024) Vol. 120, Iss. 1, pp. 96-105
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top